Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

AUTL

NASDAQ

Autolus Therapeutics (AUTL)

0.9037 USD −7.36% vs prior close Nov 20, 2026
Autolus Therapeutics plc price graph
64 sessions
2.5 0.5 24 Aug 20 Nov

The line runs 2.34 USD on 24 August through 0.9037 USD on 20 November, on a scale from 0.5 to 2.5. Days the market did not trade hold the previous close, flat.

Market cap
240.7M USD
Revenue, year to Dec 2025
75.4M USD
EPS, diluted, year to Dec 2025
−1.08 USD
52-week range
0.9037 USD – 2.54 USD
Avg volume
196.6K

as of Nov 20, 2026

Have Autolus Therapeutics (AUTL) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Autolus Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 1 Sep 2026, show no open-market purchase.

Form 4, 90 days to 22 Nov 2026, newest reported trade 2 Sep 2026

0buys
1sells
$16Knet sold
1other filings
Have Autolus Therapeutics (AUTL) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
02 Sep 2026Piccina CintiaU.S. CCO & Country Gen ManagerSell6,71316K USD
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
Have Autolus Therapeutics (AUTL) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
01 Sep 2026Piccina CintiaU.S. CCO & Country Gen ManagerOption exercise20,00047K USD

Which funds hold Autolus Therapeutics (AUTL)?

5 of the 45 institutional funds we track reported a Autolus Therapeutics position for the quarter ended 30 Sep 2026 — a combined 12.7M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Autolus Therapeutics (AUTL)?
FundPositionSharesValueShares q/q
Renaissance TechnologiesAdded2,492,9004.8M USD+25.6%
Millennium ManagementAdded2,164,1824.2M USD+76.7%
Citadel AdvisorsAdded1,630,4693.2M USD+134.3%
Point72 Asset ManagementAdded134,420261K USD+88.7%
Two Sigma InvestmentsNew position106,889207K USD
Balyasny Asset ManagementExited
Marshall WaceExited

What has been filed or recorded for Autolus Therapeutics (AUTL)?

The filings we hold for Autolus Therapeutics, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 19 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Autolus Therapeutics (AUTL)?
And
19 Oct 2026Fails to deliverShares failed to deliver2,210 shares4K USD notional · 0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.21 USD
30 Sep 2026FinancialsTotal assets523.1M USDat period end
30 Sep 2026FinancialsTotal equity27.4M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.15 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.27 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.08 USD
31 Dec 2025FinancialsRevenue75.4M USDfiscal year
31 Dec 2025FinancialsNet income−287.5M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.08 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.30 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.18 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.26 USDRevenue $9M
31 Dec 2024Annual reportFY 2024 reportedEPS −0.86 USDRevenue $10M

What do people ask about Autolus Therapeutics (AUTL)?

From live data
What did Autolus Therapeutics shares close at?0.9037

Autolus Therapeutics closed at 0.9037 USD on 20 Nov 2026, down 7.36% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Autolus Therapeutics’ market cap?240.7M

Autolus Therapeutics is worth 240.7M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Autolus Therapeutics’ revenue?75.4M

Autolus Therapeutics reported revenue of 75.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Autolus Therapeutics insiders bought or sold shares recently?1 sale

In the 90 days to 22 Nov 2026, Autolus Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 1 Sep 2026, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders

Which funds own Autolus Therapeutics?5 of 45

5 of the 45 funds we track reported a Autolus Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Millennium Management and Citadel Advisors. See Funds

When did Autolus Therapeutics last report earnings?−0.21

Autolus Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.21 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words